GC Group, a provider of healthcare solutions, agreed to acquire BioCentriq, a US-based contract development and manufacturing organization that designs and develops scalable cell and gene technologies, for $73m. “BioCentriq’s unique expertise in the rapidly growing cell and gene therapy CDMO will be a transformative addition to our business that we believe will accelerate our growth, with additional expansion projects underway adjacent to current BioCentriq facilities. We are thrilled to team up with BioCentriq’s incredibly talented team,” Yong-Jun Huh, GC Group President.